Access
Email Verification
Agenda 2021
DAY 1: TUESDAY, 29 JUNE, 2021
0900 - 0930 REGISTRATION AND MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 LEVERAGING PRIVATE PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
- International co-operation and global solidarity
- Leverage private public partnership in vaccines development
- Rules need to be set now to manage Intellectual property rights and procurement for equitable access
Anh Wartel
International Vaccine Institute
International Vaccine Institute
1010 - 1030 SPEED NETWORKING SESSION
- Exchange business cards and get connected in short one-to-one meetings
- Start the conversation to arrange a more formal meeting later on in the conference
- Share your professional background and discuss your biggest business issues - Don't forget your business cards!
Conference Host
1030 - 1100 MORNING COFFEE BREAK IN EXHIBIT AREA
1100 - 1130 DEVELOPMENT AND MANUFACTURING COVID-19 VACCINES IN A PANDEMIC SITUATION
- Case study: CEPI’s response to COVID-19
- COVID-19 vaccine global access (COVAX) facility: manufacturing SWAT team activities
Anna Särnefält
CEPI
CEPI
1130 - 1200 PANEL DISCUSSION ON VACCINE TECHNOLOGY
1200 - 1330 NETWORKING LUNCH & VISIT VACCINE TECHNOLOGY EXHIBITION
1330 - 1400 WHICH SUGAR DO YOU WANT? ENGINEERING CHO CELLS FOR THE PRODUCTION OF RECOMBINANT PROTEINS WITH TAILOR-MADE GLYCOSYLATION
- High throughput targeted engineering of CHO cells for improved production of recombinant proteins
- Toolbox: 30+ cell lines for quick production of small quantities of glycovariants for screening for optimal glycoform
- Scalable production of the preferred glycovariant from stable and robust production cell line
Bjorn Voldborg
Technical University of Denmark
Technical University of Denmark
1400 - 1430 DEVELOPMENT OF AN AUTOMATED MICROSCALE SCREENING PLATFORM FOR GLYCOCONJUGATE VACCINE PRODUCTION
- Initial scale down using kla estimations and the product expression achieved at two scales
- Development of an automated microscale screening platform
- Results from the screening platform (strain comparison and media formulation)
Jasmin Samaras
University College London
University College London
1430 - 1500 AFTERNOON COFFEE BREAK IN EXHIBIT AREA
1500 - 1530 COMBINING EVOLUTIONARY ENGINEERING WITH PROCESS INTENSIFICATION FOR IMPROVED INFLUENZA HA-VLPS PRODUCTION IN STABLE INSECT CELLS
- Adaptive laboratory evolution of stable insect cells to hypothermic culture conditions - evolutionary engineering
- High-cell-density cultures using perfusion - process intensification
- Stable insect Sf9 cell lines for influenza HA-VLPs production
Antonio Roldao
iBET
iBET
1530 - 1600 CELL-FREE SYNTHETIC SYSTEMS FOR SCALABLE AND TIMELY VACCINE MANUFACTURE
- Requirements for rapid scale-up and deployment of vaccines has accelerated the maturation of cell-free systems as an approach for commercial biologics supply
- Opportunities afforded by such an approach as well as the challenges to be overcome to improve its more widespread adoption
- Case studies to illustrate the points raised and share learnings from the work at CPI
Philip Probert
Centre for Process Innovation Limited
Centre for Process Innovation Limited
1600 - 1700 NETWORKING DRINKS RECEPTION
DAY 2: WEDNESDAY, 30 JUNE, 2021
0900 - 0930 MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 GENOME EDITING OF AVIAN HERPESVIRUSES FOR RECOMBINANT VACCINE DEVELOPMENT
- Introduction of Marek’s disease vaccines and traditional ways for making recombinant HVT vectored vaccine
- Generation of trivalent HVT vectored vaccine using CRISPR/Cas9 system
- Characterization of trivalent recombinant HVT vectored vaccine
Yongxiu Yao
The Pirbright Institute
The Pirbright Institute
1010 - 1040 NEXT GENERATION SARS COV-2 T-CELL VACCINE USING AN INTRANASAL NANOPARTICLE DELIVERY SYSTEM AND GENE BASED IMMUNODULATORS
- Elicits T-cell responses with the potential to last for 10 or more years
- Delivered intranasally to elicit local immunity in the airways and lungs, sites of viral entry and infection where first-line potent, long-term resident T cell memory responses are most critical
- Deliver a gene-based immunomodulator that stimulates trained innate immunity to ‘turbocharge’ potent and durable T cell memory responses to vaccination
Tom Tillett
MBF Therapeutics
MBF Therapeutics
1040 - 1100 MORNING COFFEE BREAK IN EXHIBIT AREA
1100 - 1130 ROLE OF PRODUCT DEVELOPMENT PARTNERSHIP IN ACCELERATING VACCINE DEVELOPMENT: EXPERIENCE FROM IVI’S TYPHOID PROGRAM
- PDPs play critical role to move the neglected disease vaccine agenda forward
- Multiple complex interrelationships affect vaccine development
- Experiences from 4 countries, 5 clinical trials from IVI’s typhoid program
Sushant Sahastrabuddhe
International Vaccine Institute
International Vaccine Institute
1130 - 1200 MVX01: A SEROTYPE-INDEPENDENT PNEUMOCOCCAL PROTEIN FUSION VACCINE CANDIDATE
- Pneumococcal PLY toxoid fused to CbpA epitopes
- MVX01 protection conferred from 17 or 20 Virulent pneumococcal serotypes
- Superior to Polysaccharide Capsular Vaccine (PCV); Synergistic with PCV
- cGMP material produced
Kevin Killeen
Matrivax Corporation
Matrivax Corporation
1200 - 1215 CLOSING REMARKS
1215 - 1330 NETWORKING LUNCH & RAFFLE DRAW
Key topics for 2021:
- The fundamentals of new vaccine discovery and development
Understand biotech and pharmaceutical industry fundamentals and key market drivers for developing vaccinations from a global perspective. - Exploring new technologies in vaccine delivery for better immune responses
Look for new opportunities and make the clinical case for adopting new technology and techniques for vaccine delivery. - Latest research in genetically-engineered vaccinations and mRNA vaccine technologies
Explore new innovations and assess the latest results from tests and trials in biologically-engineered vaccinations, as well as new advancements in DNA, messenger RNA vaccination technologies. - New developments in viral vectors, nucleic acid-based vaccines, and structural vaccinology
Future of vaccination strategies and the latest advancements in viral vector-based applications for adapting structural viral vaccine design and development. - Advances in live-attenuated virus vaccines and lessons learnt from inactivated vaccines
Hear from leading vaccine developers and build on traditional vaccine approaches for cost-effective and proven methods for developing new vaccines. - Case studies and clinical trials and working with global vaccine manufacturers
Gain insight from leading manufacturers and implement strategies that others in the industry are using to ensure successful vaccine delivery.
Sponsorship Opportunities
Join us as a sponsor for this IQ International conference! Reach your target audience, limit competitor influence at the conference and become a keynote speaker, while sharing your company's solutions for this industry.
- Get registration discounts
- Enhance your brand awareness
- Additional marketing opportunities